138 related articles for article (PubMed ID: 35349822)
21. Activation of TGF-β - SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK.
Natani S; Sruthi KK; Asha SM; Khilar P; Lakshmi PSV; Ummanni R
Cell Signal; 2022 Mar; 91():110240. PubMed ID: 34986386
[TBL] [Abstract][Full Text] [Related]
22. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
[No Abstract] [Full Text] [Related]
23. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
24. A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression.
Naderinezhad S; Zhang G; Wang Z; Zheng D; Hulsurkar M; Bakhoum M; Su N; Yang H; Shen T; Li W
Cancer Lett; 2023 Sep; 571():216333. PubMed ID: 37543278
[TBL] [Abstract][Full Text] [Related]
25. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.
Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ
PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118
[TBL] [Abstract][Full Text] [Related]
26. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
27. Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling.
Li J; Yang XM; Wang YH; Feng MX; Liu XJ; Zhang YL; Huang S; Wu Z; Xue F; Qin WX; Gu JR; Xia Q; Zhang ZG
J Hepatol; 2014 Jun; 60(6):1225-34. PubMed ID: 24607627
[TBL] [Abstract][Full Text] [Related]
28. The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.
Blanc C; Moktefi A; Jolly A; de la Grange P; Gay D; Nicolaiew N; Semprez F; Maillé P; Soyeux P; Firlej V; Vacherot F; Destouches D; Amiche M; Terry S; de la Taille A; Londoño-Vallejo A; Allory Y; Delbé J; Hamma-Kourbali Y
Br J Cancer; 2023 Mar; 128(5):918-927. PubMed ID: 36550208
[TBL] [Abstract][Full Text] [Related]
29. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
Sreekumar A; Saini S
Noncoding RNA; 2022 Mar; 8(2):. PubMed ID: 35447888
[TBL] [Abstract][Full Text] [Related]
30. MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.
Li J; Pu T; Yin L; Li Q; Liao CP; Wu BJ
Oncogene; 2020 Apr; 39(16):3305-3321. PubMed ID: 32066880
[TBL] [Abstract][Full Text] [Related]
31. The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.
Pernicová Z; Slabáková E; Fedr R; Šimečková Š; Jaroš J; Suchánková T; Bouchal J; Kharaishvili G; Král M; Kozubík A; Souček K
Mol Cancer; 2014 May; 13():113. PubMed ID: 24884804
[TBL] [Abstract][Full Text] [Related]
32. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
33. TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
Fan L; Gong Y; He Y; Gao WQ; Dong X; Dong B; Zhu HH; Xue W
Oncogene; 2023 Feb; 42(8):559-571. PubMed ID: 36544044
[TBL] [Abstract][Full Text] [Related]
34. Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.
Xu S; Adisetiyo H; Tamura S; Grande F; Garofalo A; Roy-Burman P; Neamati N
Br J Cancer; 2015 Jul; 113(2):242-51. PubMed ID: 26103574
[TBL] [Abstract][Full Text] [Related]
35. Enzalutamide-Induced Upregulation of PCAT6 Promotes Prostate Cancer Neuroendocrine Differentiation by Regulating miR-326/HNRNPA2B1 Axis.
Liu B; Jiang HY; Yuan T; Luo J; Zhou WD; Jiang QQ; Wu D
Front Oncol; 2021; 11():650054. PubMed ID: 34277403
[TBL] [Abstract][Full Text] [Related]
36. Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma.
Li PC; Siddiqi IN; Mottok A; Loo EY; Wu CH; Cozen W; Steidl C; Shih JC
J Pathol; 2017 Oct; 243(2):220-229. PubMed ID: 28722111
[TBL] [Abstract][Full Text] [Related]
37. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.
Merkens L; Sailer V; Lessel D; Janzen E; Greimeier S; Kirfel J; Perner S; Pantel K; Werner S; von Amsberg G
J Exp Clin Cancer Res; 2022 Feb; 41(1):46. PubMed ID: 35109899
[TBL] [Abstract][Full Text] [Related]
38. The role of monoamine oxidase A in HPV-16 E7-induced epithelial-mesenchymal transition and HIF-1α protein accumulation in non-small cell lung cancer cells.
Huang B; Zhou Z; Liu J; Wu X; Li X; He Q; Zhang P; Tang X
Int J Biol Sci; 2020; 16(14):2692-2703. PubMed ID: 32792865
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 Expression.
Song Z; Cao Q; Guo B; Zhao Y; Li X; Lou N; Zhu C; Luo G; Peng S; Li G; Chen K; Wang Y; Ruan H; Guo Y
Aging Dis; 2023 Oct; 14(5):1757-1774. PubMed ID: 37196108
[TBL] [Abstract][Full Text] [Related]
40. MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.
Wu JB; Yin L; Shi C; Li Q; Duan P; Huang JM; Liu C; Wang F; Lewis M; Wang Y; Lin TP; Pan CC; Posadas EM; Zhau HE; Chung LWK
Cancer Cell; 2017 Mar; 31(3):368-382. PubMed ID: 28292438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
